Biomarker analysis of WJOG6410L/IMPACT: A randomized phase III trial of adjuvant gefitinib versus cisplatin and vinorelbine in completely resected (Stage II-III) non-small cell lung cancer patients with EGFR mutatio
Not Applicable
Recruiting
- Conditions
- Completely resected (Stage II-III) non-small cell lung cancer patients with EGFR mutation
- Registration Number
- JPRN-UMIN000044738
- Lead Sponsor
- ational Cancer Center Hospital East
- Brief Summary
Multivariate analysis showed that NOTCH1 co-mutation was a significant poor prognostic factor for OS in the gefitinib group and CREBBP co-mutation for DFS and OS in the cis/vin group. In patients with NOTCH1 co-mutations, OS was shorter in the gefitinib group, with a significant interaction (P for interaction=0.039). In patients with CREBBP co-mutations, DFS was longer in the gefitinib group, with a significant interaction (P for interaction=0.058).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 211
Inclusion Criteria
Not provided
Exclusion Criteria
Not applicable
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method